# Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

> **NCT03717298** · PHASE2 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 30 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Pancreatic Cancer
- Advanced Cancer
- Digestive System Neoplasms
- Pancreatic Neoplasms
- Endocrine Gland Neoplasms
- Digestive System Diseases
- Endocrine System Diseases
- Pancreatic Diseases

## Interventions

- **DIETARY_SUPPLEMENT:** Ocoxin-Viusid®

## Key facts

- **NCT ID:** NCT03717298
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-30
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-01-20
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03717298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03717298, "Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03717298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*